Optiver Holding B.V. Sells 50,949 Shares of Smith & Nephew SNATS, Inc. $SNN

Optiver Holding B.V. lowered its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 4.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,099,953 shares of the medical equipment provider’s stock after selling 50,949 shares during the period. Smith & Nephew SNATS accounts for approximately 0.0% of Optiver Holding B.V.’s portfolio, making the stock its 23rd largest holding. Optiver Holding B.V. owned 0.26% of Smith & Nephew SNATS worth $39,917,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. GAMMA Investing LLC lifted its holdings in Smith & Nephew SNATS by 11.7% during the 3rd quarter. GAMMA Investing LLC now owns 3,837 shares of the medical equipment provider’s stock worth $139,000 after purchasing an additional 401 shares in the last quarter. Versant Capital Management Inc increased its position in shares of Smith & Nephew SNATS by 5.0% during the third quarter. Versant Capital Management Inc now owns 8,912 shares of the medical equipment provider’s stock valued at $323,000 after buying an additional 423 shares during the period. Inspire Investing LLC increased its position in shares of Smith & Nephew SNATS by 7.1% during the third quarter. Inspire Investing LLC now owns 7,789 shares of the medical equipment provider’s stock valued at $283,000 after buying an additional 516 shares during the period. Cary Street Partners Financial LLC lifted its holdings in shares of Smith & Nephew SNATS by 3.8% in the second quarter. Cary Street Partners Financial LLC now owns 20,005 shares of the medical equipment provider’s stock worth $613,000 after buying an additional 725 shares in the last quarter. Finally, MAI Capital Management boosted its position in shares of Smith & Nephew SNATS by 24.0% in the second quarter. MAI Capital Management now owns 4,371 shares of the medical equipment provider’s stock valued at $134,000 after acquiring an additional 846 shares during the period. 25.64% of the stock is currently owned by institutional investors.

Smith & Nephew SNATS Trading Down 0.7%

Smith & Nephew SNATS stock opened at $35.94 on Wednesday. Smith & Nephew SNATS, Inc. has a fifty-two week low of $23.91 and a fifty-two week high of $38.79. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00. The firm’s fifty day moving average price is $33.92 and its 200-day moving average price is $34.94.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Canaccord Genuity Group decreased their target price on shares of Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a report on Tuesday, November 11th. Wall Street Zen cut shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Saturday. Kepler Capital Markets upgraded Smith & Nephew SNATS to a “strong-buy” rating in a research report on Monday, November 17th. Royal Bank Of Canada cut Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $35.75.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.